DYN Q3 2024 Earnings — Dyne Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DYNDyne Therapeutics, Inc.

$3B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$106M

Net Income

-$97M

EPS (Diluted)

$-0.96

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$75M

Free Cash Flow

-$75M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$769M

Total Liabilities

$63M

Stockholders' Equity

$706M

Cash & Equivalents

$532M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$106M	-$62M	-69.7%
Net Income	-$97M	-$60M	-61.3%